BACKGROUND: CD14 is a key molecule in innate immunity that mediates cell activation and signaling in response to endotoxin and other bacterial wall-derived components. CD14 protein exists in soluble (sCD14) and membrane-bound forms. The correlates of sCD14 in persons undergoing long-term hemodialysis (HD) therapy are not known. We hypothesized that increased sCD14 levels in HD patients are associated with proinflammatory cytokine activation and increased mortality. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 310 long-term HD patients who participated in the Nutritional and Inflammatory Evaluation in Dialysis (NIED) Study, a cohort derived from a pool of more than 3,000 HD outpatients during 5 years in 8 DaVita maintenance dialysis facilities in the South Bay Los Angeles, CA, area. PREDICTORS: sCD14 levels in serum. OUTCOMES: 33-month mortality. RESULTS: Mean sCD14 level was 7.24 +/- 2.45 microg/mL. Tumor necrosis factor alpha level was the strongest correlate of sCD14 level (r = +0.24; P < 0.001), followed by interleukin 6 level (r = +0.18; P = 0.002), serum ferritin level (r = +0.21; P < 0.001), total iron-binding capacity (r = -0.19; P < 0.001), body mass index (r = -0.15; P = 0.008), vintage (r = +0.14; P = 0.01), low-density lipoprotein cholesterol level (r = +0.13; P = 0.03), and body fat (r = -0.11; P = 0.06). During the 33-month follow-up, 71 (23%) patients died. Multivariable Cox proportional analysis adjusted for case-mix and other nutritional and inflammatory confounders, including serum tumor necrosis factor alpha, C-reactive protein, and interleukin 6 levels, showed that compared with the lowest sCD14 tertile, sCD14 levels in the third tertile (>7.8 microg/mL) were associated with greater death risk (hazard ratio, 1.94; 95% confidence interval, 1.01 to 3.75; P = 0.04). LIMITATIONS: Survivor bias in combined incident/prevalent studies. CONCLUSIONS: Increased sCD14 level is related positively to markers of inflammation and negatively to nutritional status and is an independent predictor of mortality in long-term HD patients. Additional studies are needed to examine the usefulness of sCD14 level in risk stratification and the clinical decision-making process in HD patients.
BACKGROUND:CD14 is a key molecule in innate immunity that mediates cell activation and signaling in response to endotoxin and other bacterial wall-derived components. CD14 protein exists in soluble (sCD14) and membrane-bound forms. The correlates of sCD14 in persons undergoing long-term hemodialysis (HD) therapy are not known. We hypothesized that increased sCD14 levels in HDpatients are associated with proinflammatory cytokine activation and increased mortality. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 310 long-term HDpatients who participated in the Nutritional and Inflammatory Evaluation in Dialysis (NIED) Study, a cohort derived from a pool of more than 3,000 HD outpatients during 5 years in 8 DaVita maintenance dialysis facilities in the South Bay Los Angeles, CA, area. PREDICTORS: sCD14 levels in serum. OUTCOMES: 33-month mortality. RESULTS: Mean sCD14 level was 7.24 +/- 2.45 microg/mL. Tumor necrosis factor alpha level was the strongest correlate of sCD14 level (r = +0.24; P < 0.001), followed by interleukin 6 level (r = +0.18; P = 0.002), serum ferritin level (r = +0.21; P < 0.001), total iron-binding capacity (r = -0.19; P < 0.001), body mass index (r = -0.15; P = 0.008), vintage (r = +0.14; P = 0.01), low-density lipoprotein cholesterol level (r = +0.13; P = 0.03), and body fat (r = -0.11; P = 0.06). During the 33-month follow-up, 71 (23%) patients died. Multivariable Cox proportional analysis adjusted for case-mix and other nutritional and inflammatory confounders, including serum tumor necrosis factor alpha, C-reactive protein, and interleukin 6 levels, showed that compared with the lowest sCD14 tertile, sCD14 levels in the third tertile (>7.8 microg/mL) were associated with greater death risk (hazard ratio, 1.94; 95% confidence interval, 1.01 to 3.75; P = 0.04). LIMITATIONS: Survivor bias in combined incident/prevalent studies. CONCLUSIONS: Increased sCD14 level is related positively to markers of inflammation and negatively to nutritional status and is an independent predictor of mortality in long-term HDpatients. Additional studies are needed to examine the usefulness of sCD14 level in risk stratification and the clinical decision-making process in HDpatients.
Authors: Kamyar Kalantar-Zadeh; Noriko Kuwae; Dennis Y Wu; Ronney S Shantouf; Denis Fouque; Stefan D Anker; Gladys Block; Joel D Kopple Journal: Am J Clin Nutr Date: 2006-02 Impact factor: 7.045
Authors: Kamyar Kalantar-Zadeh; Joel D Kopple; Ryan D Kilpatrick; Charles J McAllister; Christian S Shinaberger; David W Gjertson; Sander Greenland Journal: Am J Kidney Dis Date: 2005-09 Impact factor: 8.860
Authors: Rajnish Mehrotra; Dulcie Kermah; Linda Fried; Kamyar Kalantar-Zadeh; Osman Khawar; Keith Norris; Allen Nissenson Journal: J Am Soc Nephrol Date: 2007-09-05 Impact factor: 10.121
Authors: Anna Peeters; Jan J Barendregt; Frans Willekens; Johan P Mackenbach; Abdullah Al Mamun; Luc Bonneux Journal: Ann Intern Med Date: 2003-01-07 Impact factor: 25.391
Authors: Ruben Poesen; Ali Ramezani; Kathleen Claes; Patrick Augustijns; Dirk Kuypers; Ian R Barrows; Jagadeesan Muralidharan; Pieter Evenepoel; Björn Meijers; Dominic S Raj Journal: Clin J Am Soc Nephrol Date: 2015-07-07 Impact factor: 8.237
Authors: Nazanin Noori; Csaba P Kovesdy; Ramanath Dukkipati; Usama Feroze; Miklos Z Molnar; Rachelle Bross; Allen R Nissenson; Joel D Kopple; Keith C Norris; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2011-02-04 Impact factor: 3.754
Authors: Mehdi Rambod; Gunnar H Heine; Sarah Seiler; Elizabeth A Dominic; Kyrill S Rogacev; Rama Dwivedi; Ali Ramezani; Maria R Wing; Richard L Amdur; Danilo Fliser; Dominic S Raj Journal: Atherosclerosis Date: 2014-08-12 Impact factor: 5.162
Authors: Ali Ramezani; Ziad A Massy; Björn Meijers; Pieter Evenepoel; Raymond Vanholder; Dominic S Raj Journal: Am J Kidney Dis Date: 2015-11-15 Impact factor: 8.860